Innate Pharma announces appointment of Laure-Hélène Mercier to the Executive Board
12 Février 2019 - 7:00AM
Innate Pharma announces appointment of Laure-Hélène Mercier to the
Executive Board
INNATE PHARMA ANNOUNCES APPOINTMENT OF
LAURE-HÉLÈNE MERCIER TO THE EXECUTIVE BOARD
- Appointments of Dr. Mondher
Mahjoubi, Chief Executive Officer, and Dr. Yannis Morel, EVP
Business Development and Portfolio Strategy, renewed to the
Executive Board for three years
Marseille,
France, February 12, 2019, 7:00 AM CET
Innate Pharma SA (the “Company” - Euronext
Paris: FR0010331421 – IPH) today announces that the Supervisory
Board of Innate Pharma has strengthened the Company’s leadership
and corporate governance with the appointment of Laure-Hélène
Mercier, Chief Financial Officer, as a member of the Executive
Board for a period of three years.
Laure-Hélène Mercier, MSc, MBA, has served as
the Executive Vice President and Chief Financial Officer since late
2016 and has a 10-year tenure at Innate Pharma.
The Supervisory Board has also renewed the
appointments to the Executive Board of Dr. Mondher Mahjoubi, CEO,
and Dr. Yannis Morel, EVP Business Development and Portfolio
Strategy, for three additional years.
As from January 31, 2019, the Executive Board is
now composed of three members, appointed for a three-year
period.
About Innate Pharma:
Innate Pharma S.A. is a fully integrated
oncology-focused biotech company dedicated to improving treatment
and clinical outcomes for patients through therapeutic antibodies
that harness the immune system to fight cancer.
Innate Pharma’s commercial-stage product,
Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in
September 2018. Lumoxiti is a first-in class specialty oncology
product for hairy cell leukemia (HCL). Innate Pharma’s broad
pipeline of antibodies includes several first-in-class clinical and
preclinical candidates in cancers with high unmet medical need.
Innate Pharma has pioneered the discovery and
development of checkpoint inhibitors, with a unique expertise and
understanding of Natural Killer cell biology. This innovative
approach has resulted in major alliances with leaders in the
biopharmaceutical industry including Bristol-Myers Squibb, Novo
Nordisk A/S, Sanofi, and a landmark and multi-products partnership
with AstraZeneca/MedImmune.
Based in Marseille, France, Innate Pharma is listed
on Euronext Paris.
Learn more about Innate Pharma at
www.innate-pharma.com
Information about Innate Pharma
shares:
|
ISIN codeTicker
codeLEI |
FR0010331421IPH9695002Y8420ZB8HJE29 |
Disclaimer:
This press release contains certain
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors (“Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the
AMF website www.amf-france.org or on Innate Pharma’s website.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
|
Investors Innate
Pharma Dr. Markus Metzger / Danielle Spangler
/Jérôme Marino Tel.: +33 (0)4 30 30 30 30
investors@innate-pharma.com |
International Media
Consilium Strategic Communications Mary-Jane
Elliott / Jessica Hodgson Tel.: +44 (0)20 3709 5700
InnatePharma@consilium-comms.com |
|
|
French Media ATCG
Press Solène Moulin Tel.: +33 (0)9 81 87 46 72
presse@atcg-partners.com |